ResMed (RMD) PT Raised to $76 at Barclays
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Analysts rush to cut Intel (INTC) price targets following weaker than expected Q1 guidance
- Lucid Group (LCID) doubles on Saudi rumors
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Barclays raised its price target on ResMed (NYSE: RMD) to $76.00 (from $70.00) while maintaining a Underweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
- Holcim Ltd (HOLN:SW) PT Raised to CHF53 at JPMorgan
- Sika AG (SIKA:SW) (SKFOF) PT Raised to CHF216 at JPMorgan
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!